Condition: Chronic Kidney Disease 5D · Secondary Hyperparathyroidism · Sponsor: Boryung Pharmaceutical Co., Ltd
The purpose of this study is to evaluate the efficacy and safety of pacitol Inj.(paricalcitol) for secondary hyperparathyroidism with stage 5D chronic kidney disease (CKD 5D) receiving hemodialysis
This description comes directly from the study's public registry record.
Shinyoung Oh · +82-2-708-8000 · syoh@boryung.co.kr
Always discuss trial participation with your own doctor first.
| DongGuk university Ilsan hospital | Goyang-si, Gyeonggi-do, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06126016